Recently, a single-nucleotide polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene (BDNF Val66Met) has been linked to the development of multiple forms of neuropsychiatric illness. This SNP, when genetically introduced into mice, recapitulates core phenotypes identified in human BDNF Val66Met carriers. In mice, this SNP also leads to elevated expression of anxiety-like behaviors that are not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetine. A prominent hypothesis is that SSRIinduced augmentation of BDNF protein expression and the beneficial trophic effects of BDNF on neural plasticity are critical components for drug response. Thus, these mice represent a potential model to study the biological mechanism underlying treatment-resistant forms of affective disorders. To test whether the BDNF Val66Met SNP alters SSRI-induced changes in neural plasticity, we used wild-type (BDNF Val/Val ) mice, and mice homozygous for the BDNF Val66Met SNP (BDNF Met/Met ). We assessed hippocampal BDNF protein levels, survival rates of adult born cells, and synaptic plasticity (long-term potentiation, LTP) in the dentate gyrus either with or without chronic (28-day) fluoxetine treatment. BDNF Met/Met mice had decreased basal BDNF protein levels in the hippocampus that did not significantly increase following fluoxetine treatment. BDNF Met/Met mice had impaired survival of newly born cells and LTP in the dentate gyrus; the LTP effects remained blunted following fluoxetine treatment. The observed effects of the BDNF Val66Met SNP on hippocampal BDNF expression and synaptic plasticity provide a possible mechanistic basis by which this common BDNF SNP may impair efficacy of SSRI drug treatment.
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a critical regulator of activity-dependent plasticity in the adult brain (Barde et al., 1987; Huang and Reichardt, 2001; Chao, 2003) . Genetic or environmental factors that disrupt BDNF expression or signaling have been associated with the development of a number of neuropsychiatric disorders, including major depression (Okada et al., 2006; Gatt et al., 2009; Verhagen et al., 2010) . In rodent models, nearly all antidepressant regimens tested to date increase BDNF within the adult hippocampus (Duman and Monteggia, 2006; Musazzi et al., 2009 ), a brain region heavily implicated in the expression of anxiety and depressive-like symptoms (Sahay and Hen, 2007) . In rodents, the genetic ablation of BDNF leads to a blockade in the response to standard antidepressant regimens (Monteggia et al., 2004; Adachi et al., 2008) . Furthermore, the infusion of BDNF protein into the brains of rodents has antidepressant effects (Siuciak et al., 1997; Shirayama et al., 2002) . This has led some to propose that augmentation of BDNF expression via chronic antidepressant treatment, and the subsequent trophic effects of BDNF on neural plasticity, may be one of the critical mechanisms underlying antidepressant response.
The neurotrophic hypothesis of antidepressant response has become particularly relevant given the recent discovery of a uniquely human single-nucleotide polymorphism (SNP) in the BDNF gene (BDNF Val66Met; Egan et al., 2003) . This SNP leads to a nucleotide change from G to A at position 196 and subsequent amino acid change at position 66 in the BDNF prodomain, from valine to methionine, and interferes with the trafficking of BDNF mRNA (Chiaruttini et al., 2009) , as well as a selective impairment in the activitydependent release of BDNF (Egan et al., 2003; Chen et al., 2004 Chen et al., , 2005 Chen et al., , 2006 . Human carriers of this SNP have impairments in hippocampus-dependent memories and the extinction of learned fear (Egan et al., 2003; Soliman et al., 2010) . Male BDNF Val66Met carriers have been shown to be at increased risk to develop depression, an effect that has recently been confirmed by the largest meta-analysis to date (Verhagen et al., 2010) . In addition, carriers of the BDNF Val66Met SNP that develop depression often demonstrate more severe symptoms than individuals who are non-carriers (Hwang et al., 2006; Iga et al., 2007; Sarchiapone et al., 2008; Verhagen et al., 2010) . Despite these findings, significant questions remain regarding the mechanisms underlying BDNF's contribution to the development of affective disorders and the potential role of this SNP in treatment response (Tsai et al., 2010) . Animal models have provided a fruitful testing ground to address such questions.
We have generated a mouse model in which we knockedin the BDNF Val66Met SNP into the mouse bdnf gene, replacing the endogenous BDNF. Mice homozygous for the BDNF Val66Met SNP (BDNF Met/Met ) phenocopy human SNP carriers (Chen et al., 2006; Soliman et al., 2010) and have elevated expression of anxiety-like behaviors that are unresponsive to chronic treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Thus, this mouse may provide a model system to gain insights into the mechanisms by which BDNF Val66Met suppresses the response of some individuals to SSRI treatment.
In animal models of depression, two of the potential targets of increased trophic support are through augmentation of hippocampal neurogenesis (Castren, 2004; Sahay and Hen, 2007; Schmidt and Duman, 2007) and synaptic plasticity (Manji et al., 2003; Castren, 2004; Russo-Neustadt and Chen, 2005; Wang et al., 2008) , both processes are impacted by altered BDNF levels (Figurov et al., 1996; Sairanen et al., 2005; Scharfman et al., 2005; Chan et al., 2008; Donovan et al., 2008; Li et al., 2008) . We found that BDNF Met/Met mice had decreased basal levels of BDNF in the hippocampus, and unlike BDNF Val/Val mice, BDNF protein levels did not increase following chronic fluoxetine treatment. We tested for alterations in the functional plasticity of the hippocampus under basal conditions and following chronic fluoxetine treatment in BDNF Met/Met and BDNF Val/Val mice. BDNF Met/Met mice also had fewer surviving newly born cells in the adult dentate gyrus (DG) of the hippocampus relative to BDNF Val/Val controls. Following fluoxetine treatment, neurogenesis in BDNF Met/Met mice normalized to untreated wildtype levels. Finally, we found impairments in long-term potentiation (LTP) in the DG of BDNF Met/Met mice compared with BDNF Val/Val controls, an effect that was not rescued by chronic fluoxetine treatment. These studies are the first to identify impairments in BDNF protein expression, the incorporation of newly born cells, and synaptic plasticity in the DG of adult BDNF Met/Met mice. Furthermore, these studies provide a possible mechanistic framework through which the BDNF Val66Met SNP could impair SSRI response.
MATERIALS AND METHODS

Mice
All mice used in these studies were adult males (3-4 months of age), housed in standard shoebox cages on a 12 : 12 reverse light/dark schedule. BDNF knockout mice as described in (Lyons et al., 1999) and TrkB knockout mice as described in (Klein et al., 1989) along with wild-type littermate controls were also used for cell survival studies. For the remainder of studies, BDNF Val66Met knock-in mice (BDNF Met/Met ) and wild-type (BDNF Val/Val ) littermate controls as described in (Chen et al., 2006) were used. All mouse lines were fully backcrossed (minimum of 10 generations) onto an inbred C57BL/6 background. Animal care was in accordance with Weill Medical College of Cornell University IACUC and FDA standards.
Tissue Preparation and Immunohistochemistry
Control and genetically modified lines of mice were deeply anesthetized with pentobarbital and transcardially perfused with a solution of 0.9% saline and 0.1% sodium nitrite followed by 4% paraformaldehyde in phosphate buffer. Brains were dissected out and postfixed in 4% paraformadehyde for 1 h. Brains were then incubated in a 30% sucrose solution overnight at 41C. Coronal sections were serially cut at 40 mm using a freezing microtome. Immunohistochemistry was performed on floating sections. Briefly, sections were first incubated in a blocking solution for 1 h and then transferred to the primary antibody solution for 48 h at 41C before incubation with the corresponding fluorescentlabeled (Invitrogen, Carlsbad, CA) or biotinylated secondary antibody (Vector Laboratories, Burlingame, CA). Antibodies and dilutions used included a rabbit polyclonal anti-pTrkB (1 : 500), anti-NeuN (Millipore; 1 : 1000), antipolysialylated neural cell adhesion molecule (PSA-NCAM; Millipore; 1 : 400), anti-GFAP (Millipore; 1 : 1000), antiBrdU (BD Biosciences; 1 : 200). BrdU-labeled sections were analyzed using a standard Nikon (Tokyo, Japan) upright microscope, digital camera mount, and the MetaMorph software package (Molecular Devices, Sunnyvale, CA). For co-labeling studies we performed confocal fluorescence microscopy using a Zeiss (Oberkochen, Germany) LSM510 microscope fitted with a Zeiss Â 63 1.4 numerical aperture objective with standard filter sets and a standard (1 Airy disk) pinhole.
Fluoxetine Administration
Fluoxetine was dissolved in water (160 mg/l, as described in (Dulawa et al., 2004) ) and administered in light-protected water bottles. Fluoxetine infused water was changed every 72 h to insure fresh and active drug. Inclusion of fluoxetine led to no change in water consumption, and based on the average daily water intake of mice (3.1 ml per mouse, per day with a range of 2.5-3.8 ml), this concentration led to an average daily dose of 0.5 mg of fluoxetine per day (or B16 mg/kg). This dosing regimen has been shown to lead to therapeutic levels in blood and to be highly effective in reducing anxiety-like symptoms in standard inbred mouse strains (Dulwala et al., 2004; Dulwala and Hen, 2005) .
BDNF ELISA
To measure endogenous BDNF levels, a BDNF enzymelinked immunosorbent assay (ELISA) was used (BDNF Emax Immunoassay System, Promega, Madison, WI) with recombinant BDNF as a standard. This methodology demonstrates low cross-reactivity (o3%) with other neurotrophic factors and is capable of detecting a minimum of 15.6 pg/ml of BDNF. Briefly, control and fluoxetine treated BDNF Val/Val and BDNF Met/Met mice were killed by cervical dislocation and then decapitation. Brains were collected on ice and total bilateral hippocampi were dissected and then lysed in 700 ml TNE lysis buffer (0.1 M Tris HCl, 0.15 M NaCl, 0.001 M EDTA, 1% NP-40). Lysates were centrifuged for 10 min at 41C and the clarified supernatant was collected. Using the Bradford method, total levels of protein were quantified. Tissue and assay were prepared and run in accordance with the manufacturers suggested protocol. BDNF levels were then corrected based on the total amount of protein loaded.
BrdU Labeling, Detection, and Quantification
BrdU labeling and immunohistochemcial detection was carried out as described in Bath et al. (2008) . To quantify the density of BrdU positive cells in the sub-granular & granule cell layer of the DG, a profile counting method was used (described below). To estimate the rate of survival of newly born cells, mice were given a single injection of BrdU (160 mg/kg) and allowed to survive for 4-weeks prior to sacrifice. To avoid double counting, every third serially obtained section (80 mm interval) and was counterstained with Nissl to allow discrimination of individual cells that may be clustered. All BrdU-positive nuclei within the granule cell layer of the DG were counted. The total number of counted cells was then divided into the total volume measured in order to obtain an estimate of the density of BrdU positive cells within this structure.
LTP and Basal Transmission in DG
Control or fluoxetine treated mice were killed by decapitation after pentobarbital anesthesia. Brains were quickly removed and placed in ice-cold artificial cerebrospinal fluid (ACSF) consisting of (in mM): NaCl (118), KCl (4.4), CaCl 2 (2), MgCl 2 (2), NaHCO 3 (26), NaH 2 PO 4 (1), D-glucose (10) aerated by 95% O 2 / 5% CO 2 (pH 7.4; Ninan et al., 2010) . Hippocampi were quickly removed. Transverse hippocampal slices (400 mm) were cut and transferred to a slice preincubator (Scientific System Design, Canada) at room temperature for at least 1-h to allow for recovery. A single slice was then transferred to an interface-recording chamber maintained at 32 1C (Scientific System Design, Canada). The chamber was continuously perfused by ACSF at a constant rate of 2 ml/min. Recording electrodes were filled with 2 M NaCl solution and field excitatory postsynaptic potentials (fEPSPs) were recorded from the molecular layer of the DG with IE-210 amplifier (Warner Instruments, USA) using Digidata 1440A and pClamp 10 software (Molecular Devices, USA). The stimulating electrode (concentric bipolar electrodes, FHC, Bowdoinham, ME) was placed in the medial perforant path (MPP) and stimulated using a Digital stimulator PG4000A (Cygnus Technology, PA) and stimulus isolator A365 (World Precision Instruments, Sarasota, FL). MPP-DG pathway was confirmed by assessing paired-pulse depression (PPD) at 50 ms inter-pulse interval (McNaughton, 1980; Wang et al., 2008) . After obtaining stable basal recording, input-output curves were generated. A 15-minute baseline was recorded every 20 s at an intensity that evoked a response approximately 35% of the maximum evoked response. LTP was induced using 100 Hz stimulation (4 trains, 100 Hz for 1 min, separated by 20 s). Responses were recorded for 1 h after tetanization and measured fEPSP slope expressed as percentage of baseline.
Statistics
For comparisons in which greater than two groups were included, a one-way analysis of variance (ANOVA) was used. In the event of a significant main effect, post hoc group comparisons were made using a least significant differences (LSD) approach, correcting for multiple tests. In cases in which two-groups were compared, we used Student's t-test. For all statistics a-value was set at o0.05. SPSS software (IBM) was used for all analyses.
RESULTS
Chronic Fluoxetine Fails to Normalize Hippocampal BDNF Levels in BDNF Met/Met Mice
In rodent models, nearly all antidepressant regimens tested to date have been shown to increase BDNF protein levels in the hippocampus and other brain regions (Duman and Monteggia, 2006) , an effect implicated in antidepressant efficacy. To test if the BDNF Val66Met polymorphism affects basal or SSRI-related augmentation of hippocampal BDNF protein levels in mice, we used a BDNF ELISA. We found a significant main effect of group (ANOVA, F (3,35) ¼ 6.058, po0.002). More specifically, we found that BDNF protein levels in untreated BDNF Met/Met mice were significantly lower than that observed in untreated wildtype (BDNF Val/Val ) mice (post hoc LSD, po0.01; Figure 1 ). As anticipated, following 28-days of fluoxetine treatment, Figure 1 Bar graphs depicting BDNF protein levels (pg/mg of protein) in hippocampal lysates from adult wild-type (control n ¼ 11, fluox n ¼ 11; BDNF Val/Val ) and BDNF Val66Met homozygous (control n ¼ 9, fluox n ¼ 11; BDNF Met/Met ) mice maintained for 28 days on water (Control) or 160 mg/l fluoxetine (Fluox); * indicates significant difference, po0.05. N.S., not significant difference.
BDNF
Val/Val mice showed a significant increase in BDNF protein levels compared with untreated BDNF Val/Val controls (post hoc LSD, po0.01; Figure 1) In previous reports, the genetic ablation of BDNF or TrkB in mice leads to a selective loss of surviving newly born but not proliferating cells of the DG (Bergami et al., 2008; Chan et al., 2008; Bergami et al., 2009; Gao and Chen, 2009 ). Furthermore, during neurogenesis, the BDNF receptor, TrkB, is selectively expressed by postmitotic neuroblasts and neurons (Donovan et al., 2008) . The loss of BDNF alters the neuronal fate of these cells and leads to decreased dendritic complexity of differentiated DG neurons (Chan et al., 2008) . Using immunohistochemical labeling for the phosphorylated form of TrkB (pTrkB), we found pTrkB to be most highly expressed on immature (PSA-NCAMpositive) neuroblasts (Bath et al., 2008) . In the rostral migratory stream pTrkB expression was not detectable on GFAP-positive or NeuN-positive cells (Bath et al., 2008) . These effects were identical to what we observed in the DG (Supplementary Figure 1) . On the basis on these observations, we focused our investigation of BDNF-mediated effects following fluoxetine treatment upon measures of cell survival within the DG. We used BrdU labeling (Supplementary Figure 2) to test if altered BDNF or TrkB expression impacts the survival of newly born cells of the adult DG. Consistent with previous reports (Sairanen et al., 2005; Chan et al., 2008) , the density of BrdU-positive cells in the DG of heterozygous BDNF knock-out mice (BDNF + /À ) was significantly lower than that observed in wild-type littermate controls (BDNF + / + ; Student's t-test, t(6) ¼ 5.74, po0.01; Figure 2a) . Similarly, genetic ablation of one copy of the trkb gene (TrkB + /À ) resulted in a significant reduction in the density of surviving newly born granule cells in the DG (Student's ttest, t(6) ¼ 2.44, po0.05; Figure 2b) Figure 2c ).
Impact of Chronic Fluoxetine on Cell Survival in the DG of BDNF Met/Met Mice
Chronic antidepressant treatment has been shown to augment the survival of newly born cells in the adult DG (Castren, 2004) . To test whether the BDNF Val66Met polymorphism altered the antidepressant-induced increase in cell survival, we again used BrdU labeling to track cell survival. We found a significant main effect of group (ANOVA, F (3, 20) ¼ 6.257, po0.01; Figure 3 
BDNF Met/Met Impairs Synaptic Plasticity Within the Dentate Gyrus
Earlier studies have demonstrated that chronic fluoxetine treatment can enhance synaptic neurotransmission and plasticity in the DG (Wang et al., 2008) . We tested whether the BDNF Val66Met polymorphism interfered with the fluoxetine-induced enhancement of synaptic transmission (fEPSP) and synaptic plasticity (LTP) in the DG. We analyzed PPD to confirm the MPP-DG pathway and to determine whether this short-term plasticity was modified by the BDNF Val66Met polymorphism or fluoxetine treatment (McNaughton, 1980; Wang et al., 2008 Figure 4a ). Our results are consistent with the earlier report that chronic fluoxetine decreased PPD at the MPP-DG synapses and this effect might be independent of neurogenesis (Wang et al., 2008) . However, the suppression of PPD in fluoxetine-treated BDNF Met/Met did not reach statistical significance (ANOVA followed by post hoc comparison, p40.05). Input-output relationship analysis of fEPSP slope revealed no significant differences in basal synaptic neurotransmission between untreated BDNF Met/Met and matched BDNF Val/Val mice (Two-way ANOVA, p40.05, Figure 4b ). Although fluoxetine treatment induced a robust enhancement of basal synaptic neurotransmission in the BDNF Val/Val mice (Twoway ANOVA, F (1,14) ¼ 14.5, po0.01, Figure 4b ), fluoxetinetreated BDNF Met/Met mice revealed a slight but statistically nonsignificant enhancement of basal synaptic neurotransmission compared with the untreated mice (p40.05, Figure 4b ). As the long-lasting potentiation in the MPP-DG pathway in the absence of GABA blockers is sensitive to the incorporation of new cells into the hippocampus (Snyder et al., 2001; Saxe et al., 2006; Wang et al., 2008) , we hypothesized that impaired survival of newly 
DISCUSSION
In this report, we provide the first mechanistic links between the BDNF Val66Met polymorphism and SSRI drug resistance. We found that BDNF Met/Met mice had decreased basal levels of hippocampal BDNF and did not show antidepressant-induced augmentation of BDNF protein levels. BDNF Met/Met mice had impairments in the survival of newly born cells in the DG, an effect that was normalized to control wild-type levels by SSRI treatment. Finally, we observed a blunting of synaptic plasticity within the DG of BDNF Met/Met mice, an effect that could not be rescued with the SSRI fluoxetine. These studies identify several potential mechanisms underlying blunted treatment response in mice that are homozygous for the BDNF Val66Met SNP, and may have implications for understanding mechanisms underlying treatment non-responsiveness in human populations.
Under baseline conditions, BDNF Met/Met mice had significantly lower BDNF protein levels in the hippocampus compared with control BDNF Val/Val mice. In previous reports, we have shown that the BDNF Val66Met SNP does not lead to a reduction in total BDNF levels in the whole brain of BDNF Met/Met mice, cultured cortical neurons from BDNF Met/Met mice (Chen et al., 2006) , or cortical tissues (Bath et al., 2008) . This SNP does lead to a decrease in the trafficking of BDNF to secretory vesicles and the subsequent activity-dependent release of BDNF (Egan et al., 2003; Chen et al., 2004 Chen et al., , 2005 . As the hippocampus is target of many cortical and subcortical projections, the decreased levels of BDNF could in part be due to decreased BDNF secretion from afferent inputs to the hippocampus. In recent reports, the BDNF Val66Met SNP has also been shown to impact trafficking of BDNF mRNA to dendritic processes where it can be locally transcribed (Chiaruttini et al., 2009) . Reduced transport and local translation of BDNF mRNA in BDNF Met/Met mice may also contribute to the lower protein expression observed in the hippocampus. Such effects may contribute to previously described alterations in dendritic complexity of hippocampal neurons of BDNF Met/Met mice (Chen et al., 2006) . However, further studies are required to fully understand the basis of this marked decrease in basal hippocampal BDNF protein levels.
BDNF
Met/Met mice had significantly fewer surviving newly born cells in the DG compared with BDNF Val/Val mice. Disruptions in neurogenesis have been reliably linked with the development of anxiety-like behavior and antidepressant response in animal models of anxiety and depressivelike disorders (Santarelli et al., 2003 ). Here we demonstrate that cell survival is impaired in the DG of BDNF Met/Met mice, an effect that is correlated with their development of anxiety-like behaviors. We further show that SSRI's can significantly potentiate the survival of cells in the DG of BDNF Met/Met mice. These data could suggest that SSRIinduced augmentation in newly born cell survival may not be critical for the behavioral effects of antidepressants in BDNF Met/Met mice. Alternatively, animals that have had a chronic blunting in the survival of adult born cells throughout life may simply not benefit from the modest yet significant increase in cell survival (eg the degree to which cell survival increased may have been simply insufficient).
We have shown that the BDNF Val66Met SNP leads to decreased trafficking of BDNF into secretory granules (Chen et al., 2004 and thus a reduction in the activitydependent release of BDNF (Egan et al., 2003; Chen et al., 2005 Chen et al., , 2006 . In BDNF Val66Met mice, we anticipate that the reduced activity-dependent release of BDNF onto immature cells and thus a decrease in critical trophic support during the process of cellular differentiation is the critical underlying factor leading to decreased survival of newly born cells. Such findings are consistent with previously published reports demonstrating that the genetic or pharmacological ablation of BDNF results in decreased adult neurogenesis within the hippocampus (Sairanen et al., 2005; Chan et al., 2008; Choi et al., 2009) , with specific effects on the maturation and survival of newly born neurons and the selective expression and activation of the BDNF receptor TrkB on postmitotic neuroblasts.
We uncovered significant impairments in synaptic plasticity in the dentate gyrus of BDNF Met/Met mice, under both basal conditions and following chronic fluoxetine treatment. We have recently described significant effects of this SNP on synaptic transmission and plasticity at the CA3-CA1 synapse (Ninan et al., 2010) . To our knowledge, these are the first studies to identify impairments in synaptic plasticity resulting from the BDNF Val66Met SNP in the DG. On the basis of our observations, SSRI-induced augmentations in LTP were completely blocked in BDNF Met/Met mice an effect that parallels the failure of these mice to show behavioral benefits of antidepressant treatment. Despite the rescue of neurogenesis to control levels, fluoxetine failed to reverse LTP impairment in BDNF Met/Met mice. These results suggest that fluoxetine affects plasticity by mechanisms other than neurogenesis. The lack of effect of fluoxetine on BDNF levels or a potential alteration of synaptic function might be responsible for fluoxetine-resistant LTP impairment in BDNF Met/Met mice (Colino and Malenka, 1993; Ninan et al., 2010) . BDNF has reliably been shown to be a significant promoter of synaptic excitability and LTP within the hippocampus (Minichiello, 2009 ) and the loss of TrkB from newborn neurons in this region significantly impact LTP (Bergami et al., 2008) . We hypothesize that the observed effects of BDNF Met/Met on synaptic functions are in large part due to a general decrease in the availability of BDNF in BDNF Met/Met mice as a result of impairments in activity dependent BDNF secretion. However, given the potential impact of this SNP on trafficking of BDNF mRNA to dendrites, we cannot rule out the potential role of alterations in postsynaptic BDNF expression as a contributing factor to this effect.
In conclusion, these findings provide some of the first mechanistic links between the BDNF Val66Met SNP and the development of SSRI-resistant anxiety-like behaviors. Thus, these mice may provide a useful model system to test novel therapeutic strategies to rescue anxiety and depressive-like symptoms that are unresponsive to standard drug regimens. Furthermore, such a model system may be important for understanding the mechanisms underlying treatment response to common antidepressant and anxiolytic drugs and the contribution of genetic variation to treatment outcome.
